Morgan Stanley Deal Makes it a Good Time to Add to This Biotech Name
A $23 million move by the small-cap concern has me looking to increase my position.
These Biopharma Names Don’t Have the Flash of SpaceX, but They’re Reliable
Here are four biotech plays that should stand up if the market starts to break down.
AI Trade Sees Remarkable Rotation as Market Concerns Grow
I’m buying two promising biotech names as the market grows more nervous.
I’m Stalking These Small-Caps as Interest Rates Spread Ugliness Across Wall St.
Higher interest rates are smacking the market, but I’m focusing on these opportunities.
Looking Past the AI Leaders: Why I Bought This Biotech After Earnings
Stock picking is coming back to life. Here’s an example of a name that offers lower risk after earnings news.